| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dd5b79ce904c4142242fe15d7274ef08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_93a1f161b0ab6f70e2a0df438c925c5f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed28726de9f916f355f8adc331e736b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ecf0b6b5a0c1dd4177e6cd2e88afff5d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5a19b6df232ba71e089bd67854ae7bdf |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-322 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2011-08-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e72f8a18476cb4fd801427cf4203c60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1b28b0105e5d8cc7fc3667b99c96407
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e18c5b7632b562cebf31edf817810b3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d88a149725a04277ea8df831cd65b3b |
| publicationDate |
2013-06-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2013150431-A1 |
| titleOfInvention |
Mir-33 inhibitors and uses thereof |
| abstract |
The miRNA miR-33 is shown to inhibit the expression of carnitine O-octaniltransferase (CROT), Carnitine palmitoyltransferase 1A (CPT1a) and hydroxyacyl-CoA-dehydrogenase (HADHB), reduce fatty acid oxidation in hepatic cells, and target the insulin receptor substrate 2 (IRS-2) independent of its ability to elevating plasma high density lipoprotein (HDL) levels. MiR-33 inhibitors are also shown to increase cholesterol efflux from peripheral cells, such as cholesterol-laden macrophages present in atherosclerotic plaques. Compositions and methods are therefore provided for treating or preventing metabolic syndrome and atherosclerosis using miR-33 inhibitors. The miR-33 inhibitors are preferably antagomirs having a single-stranded nucleic acid sequence that is complementary to at least 12 contiguous nucleotides in miR-33 and therefore forms a duplex with miR-33 under physiological conditions. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10612021-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11561335-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017226508-A1 |
| priorityDate |
2010-08-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |